Multi-omic analysis of Colorectal Cancer Peritoneal Metastases V1.0
Research type
Research Study
Full title
COLOMET II: Characterisation of colorectal cancer peritoneal metastases by genomic and transcriptomic analysis and correlation with clinical outcomes
IRAS ID
310705
Contact name
Omer Aziz
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 4 days
Research summary
The peritoneum is the second most common site for recurrence in colorectal cancer (CRC). Cancer spread to the peritoneum (colorectal cancer peritoneal metastases, CRPM) cause severe symptoms in patients and lead to shortened survival. Understanding how genetic mutations evolve in CRPM and the role of the tumour microenvironment are important for optimising treatment and prevent cancer metastases.
This study proposes completing cancer genetic profiling on archived (stored) tissue removed routinely from patients who had surgery for CRPM. High through-put laboratory techniques for analysing the genetic profile of CRC and CRPM has the power to identify mutation patterns than might predict for treatments and survival. The results of genetic tests can be compared to clinical characteristics. Genes in the primary CRC tumour can be compared to CRPM to describe changes during the metastatic process.
Patients who had surgery for CRPM and have stored tissue are eligible for this study. The study will be conducted by the research group at The Christie Peritoneal Oncology Centre. There is an existing MCRC Biobank Institutional Board Review with ethics approval for consented patients and use of tissue in this way. We seek a waiver of consent under the exceptions to the Human Tissue Act of 2004 (c30) for deceased patients, who have not had the opportunity to consent. We feel it is important to include deceased patients, as these may represent a group with different tumour biology.
This study will help make progress towards better treatment options, identify predictors of treatment success and long-term survival. Improved treatments and better selection of patients may ultimately improve quality of life and help patients live longer.
REC name
North West - Haydock Research Ethics Committee
REC reference
22/NW/0353
Date of REC Opinion
18 Nov 2022
REC opinion
Favourable Opinion